DNA-interleukin-2

Drug Profile

DNA-interleukin-2

Alternative Names: DNA-IL2

Latest Information Update: 01 Jul 2016

Price : $50

At a glance

  • Originator Farmacore
  • Class Cancer vaccines; DNA; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer; Oropharyngeal cancer

Most Recent Events

  • 30 Jun 2016 Preclinical development is ongoing in Brazil
  • 10 Sep 2014 Preclinical trials in Cervical cancer in Brazil (Parenteral)
  • 10 Sep 2014 Preclinical trials in Oropharyngeal cancer in Brazil (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top